ArticleEuropean journal of medical research2026
Effects of exogenous detemir and glargine insulin on the detection of endogenous C-peptide and endogenous insulin.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsTo examine the effects of administering detemir and glargine insulin on the detection of endogenous C-peptide and insulin levels.
methodsThis study enrolled 69 patients with type 2 diabetes (T2DM) who use long-acting insulin therapy. Fasting and postprandial blood glucose (BG), C-peptide, and insulin were detected for two consecutive mornings. Fasting and postprandial C-peptide/BG and insulin/BG were then compared between groups treated with or without detemir and glargine insulin the night before. Thirty patients with type 1 diabetes (T1DM) verified the results.
resultsIn patients with T2DM, compared with the results obtained from the group that did not administer insulin the night prior to testing, fasting C-peptide (CP0h), CP0h/fasting blood glucose (FBG), fasting insulin (INS0h), and INS0h /FBG were decreased with the use of detemir. Similarly, CP0h and CP0h/FBG were decreased in the group that had glargine administered the night before testing. However, there was no significant difference in INS0h and INS0h/FBG with and without the use of glargine insulin. The use of long-acting insulin had no effect on the postprandial C-peptide/PBG and postprandial insulin/PBG. In patients with T1DM, CP0h/FBG was hardly detected and had no difference between glargine and detemir groups. However, after using detemir the night before, the INS0h/FBG was hardly detected; insulin could be detected in the glargine group.
conclusionsExclusive dependence on C-peptide levels as a primary metric for the direct evaluation of pancreatic function under insulin therapy is insufficient. A comprehensive assessment necessitates due consideration of the insulin type employed for quantifying insulin and C-peptide concentrations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.